Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Malignant Melanoma

  Free Subscription


Articles published in Br J Dermatol

Retrieve available abstracts of 134 articles:
HTML format
Text format



Single Articles


    January 2019
  1. JIYAD Z, Akhras V
    Incidence of melanoma and outcomes of longitudinal melanonychia in a cohort of cases referred to a London dermatology department.
    Br J Dermatol. 2019 Jan 4. doi: 10.1111/bjd.17607.
    PubMed     Text format     Abstract available


  2. SCHILLING B, Wiesner T
    Tackling melanoma by adjuvant therapy: why, whom and how?
    Br J Dermatol. 2019;180:1-2.
    PubMed     Text format    


  3. VAN AKKOOI ACJ, Hayes A
    Recent developments in lymph node surgery for melanoma.
    Br J Dermatol. 2019;180:5-7.
    PubMed     Text format    


    December 2018
  4. MIURA K, Olsen CM, Rea S, Marsden J, et al
    Do airline pilots and cabin crew have raised risks of melanoma and other skin cancers? Systematic review and meta-analysis.
    Br J Dermatol. 2018 Dec 26. doi: 10.1111/bjd.17586.
    PubMed     Text format     Abstract available


  5. FENTON GL, Smit AK, Keogh L, Cust AE, et al
    Exploring the Emotional and Behavioural Reactions to Receiving Personalised Melanoma Genomic Risk Information: A Qualitative Study.
    Br J Dermatol. 2018 Dec 22. doi: 10.1111/bjd.17582.
    PubMed     Text format     Abstract available


  6. NAJERA L, Alonso-Juarranz M, Garrido M, Ballestin C, et al
    Prognostic implications of markers of the metabolic phenotype in human cutaneous melanoma.
    Br J Dermatol. 2018 Dec 7. doi: 10.1111/bjd.17513.
    PubMed     Text format     Abstract available


  7. FOX JA, Langbecker D, Rosenberg J, Ekberg S, et al
    Uncertain diagnosis and prognosis in advanced melanoma: A qualitative study of the experiences of bereaved carers in a time of immune and targeted therapies.
    Br J Dermatol. 2018 Dec 4. doi: 10.1111/bjd.17511.
    PubMed     Text format     Abstract available


    November 2018
  8. CORRIE PG, Terheyden P, Ten Tije AJ, Herbst R, et al
    A prospective, observational safety study of patients with BRAF(V) (600) -mutated unresectable or metastatic melanoma treated with vemurafenib [Zelboraf Safety Study (ZeSS)].
    Br J Dermatol. 2018 Nov 29. doi: 10.1111/bjd.17465.
    PubMed     Text format     Abstract available


  9. POTRONY M, Puig-Butille JA, Ribera-Sola M, Iyer V, et al
    POT1 germline mutations but not TERT promoter mutations are implicated in melanoma susceptibility in a large cohort of Spanish melanoma families.
    Br J Dermatol. 2018 Nov 19. doi: 10.1111/bjd.17443.
    PubMed     Text format     Abstract available


  10. MAEDA T, Yoshino K, Nagai K, Oaku S, et al
    Efficacy of nivolumab monotherapy against acral lentiginous melanoma and mucosal melanoma in Asian patients.
    Br J Dermatol. 2018 Nov 17. doi: 10.1111/bjd.17434.
    PubMed     Text format     Abstract available


  11. OKIYAMA N, Inoue S, Saito A, Nakamura Y, et al
    Antihelix/helix violaceous macules in Japanese patients with anti-melanoma differentiation-associated protein 5 (MDA5) antibody-associated dermatomyositis.
    Br J Dermatol. 2018 Nov 15. doi: 10.1111/bjd.17431.
    PubMed     Text format     Abstract available


  12. VERAITCH O, Lewis F, Craythorne E, Calonje E, et al
    Management of vulval melanoma in situ with imiquimod.
    Br J Dermatol. 2018 Nov 15. doi: 10.1111/bjd.17433.
    PubMed     Text format     Abstract available


    October 2018
  13. VERYKIOU S, Alexander M, Edwards N, Plummer R, et al
    Harnessing autophagy to overcome MEK-inhibitor induced resistance in metastatic melanoma.
    Br J Dermatol. 2018 Oct 19. doi: 10.1111/bjd.17333.
    PubMed     Text format     Abstract available


    September 2018
  14. KOREKAWA A, Akasaka E, Rokunohe D, Fukui T, et al
    Nagashima-type palmoplantar keratoderma and malignant melanoma in Japanese patients.
    Br J Dermatol. 2018 Sep 26. doi: 10.1111/bjd.17251.
    PubMed     Text format     Abstract available


  15. ROGIERS A, Thomas D, Vander Borght S, van den Oord JJ, et al
    Dabrafenib plus trametinib in BRAF K601E-mutant melanoma.
    Br J Dermatol. 2018 Sep 24. doi: 10.1111/bjd.17250.
    PubMed     Text format     Abstract available


  16. XU S, Stump TK, Jain J, Alshurafa N, et al
    Variation in daily ultraviolet light exposure and sun protection behaviours of melanoma survivors: an observational single-arm pilot study with a wearable sensor.
    Br J Dermatol. 2018 Sep 12. doi: 10.1111/bjd.17196.
    PubMed     Text format     Abstract available


  17. BRANCACCIO G, Napolitano S, Troiani T, Franco R, et al
    Eighth American Joint Committee on Cancer (AJCC) melanoma classification: what about stage IIC?
    Br J Dermatol. 2018 Sep 5. doi: 10.1111/bjd.17145.
    PubMed     Text format     Abstract available


  18. MATTHEWS NH, Risica PM, Ferris LK, Beatson M, et al
    Psychosocial impact of skin biopsies in the setting of melanoma screening - A cross-sectional survey.
    Br J Dermatol. 2018 Sep 5. doi: 10.1111/bjd.17134.
    PubMed     Text format     Abstract available


    August 2018
  19. CUST AE, Aitken J, Baade P, Whiteman D, et al
    Why a randomised melanoma screening trial may be a good idea.
    Br J Dermatol. 2018 Aug 13. doi: 10.1111/bjd.17089.
    PubMed     Text format     Abstract available


  20. VAN DOORN R
    Methylation marks melanoma metastasis.
    Br J Dermatol. 2018;179:250-251.
    PubMed     Text format    


    June 2018
  21. FARAH M, Nagarajan P, Curry JL, Tang Z, et al
    Spitzoid melanoma with histopathologic features of ALK gene rearrangement exhibiting ALK copy number gain: A novel mechanism of ALK activation in spitzoid neoplasia.
    Br J Dermatol. 2018 Jun 13. doi: 10.1111/bjd.16881.
    PubMed     Text format     Abstract available


  22. HALVORSEN JA, Loberg M, Gjersvik P, Roscher I, et al
    Why a randomized melanoma screening trial is not a good idea.
    Br J Dermatol. 2018 Jun 12. doi: 10.1111/bjd.16784.
    PubMed     Text format    


  23. PODLIPNIK S, Moreno-Ramirez D, Carrera C, Barreiro A, et al
    Cost-effectiveness analysis of imaging strategy for an intensive follow-up of patients with AJCC stage IIB, IIC and III malignant melanoma.
    Br J Dermatol. 2018 Jun 7. doi: 10.1111/bjd.16833.
    PubMed     Text format     Abstract available


  24. STENEHJEM JS, Veierod MB, Nilsen LT, Ghiasvand R, et al
    Anthropometric factors and Breslow thickness: Prospective data on 2570 cutaneous melanoma cases in the population-based Janus Cohort.
    Br J Dermatol. 2018 Jun 1. doi: 10.1111/bjd.16825.
    PubMed     Text format     Abstract available


    May 2018
  25. WAN MT, Ming ME
    Nivolumab versus ipilimumab in the treatment of advanced melanoma: a critical appraisal.
    Br J Dermatol. 2018 May 15. doi: 10.1111/bjd.16785.
    PubMed     Text format     Abstract available


  26. CAYUELA A, Cayuela L, Rodriguez-Dominguez S, Lorente AI, et al
    Is melanoma mortality declining in Spain? Analysis of trends 1975-2016.
    Br J Dermatol. 2018 May 14. doi: 10.1111/bjd.16777.
    PubMed     Text format     Abstract available


  27. FUJISAWA Y
    Baseline neutrophil-to-lymphocyte ratio in patients with advanced melanoma treated with immune checkpoint inhibitors: reply from the authors.
    Br J Dermatol. 2018 May 7. doi: 10.1111/bjd.16689.
    PubMed     Text format    


  28. KRAEMER KH, Tamura D, Khan SG
    Pembrolizumab treatment of a patient with xeroderma pigmentosum with disseminated melanoma and multiple nonmelanoma skin cancers.
    Br J Dermatol. 2018;178:1009.
    PubMed     Text format    


    April 2018
  29. RAUWERDINK DJW, Roach REJ, Etty M, Kukutsch NA, et al
    Melanoma diagnosis during periodic surveillance of patients with multiple atypical naevi.
    Br J Dermatol. 2018 Apr 28. doi: 10.1111/bjd.16708.
    PubMed     Text format     Abstract available


  30. LANGAN EA, Gratz V, Billmann F, Zillikens D, et al
    Does the gastrointestinal microbiome contribute to the "obesity paradox" in melanoma survival?
    Br J Dermatol. 2018 Apr 16. doi: 10.1111/bjd.16681.
    PubMed     Text format     Abstract available


  31. KIM J, Kim YH, Park B, Seo HM, et al
    Multispectral ex vivo photoacoustic imaging of cutaneous melanoma for better selection of the excision margin.
    Br J Dermatol. 2018 Apr 16. doi: 10.1111/bjd.16677.
    PubMed     Text format     Abstract available


  32. MACHET L, Zaragoza J, Finon A, Garnier M, et al
    Baseline neutrophil to lymphocyte ratio in patients with advanced melanoma treated with immune check point inhibitors.
    Br J Dermatol. 2018 Apr 16. doi: 10.1111/bjd.16675.
    PubMed     Text format     Abstract available


  33. HAAS L, Wiesner T, Obenauf AC
    A new era of proactive melanoma therapy: hit hard, hit early.
    Br J Dermatol. 2018;178:817-820.
    PubMed     Text format    


    March 2018
  34. VU M, Adler NR, Wee E, Wolfe R, et al
    Impact of naevus association on survival for nodular and superficial spreading melanomas.
    Br J Dermatol. 2018 Mar 24. doi: 10.1111/bjd.16556.
    PubMed     Text format     Abstract available


  35. FORSCHNER A, Keim U, Hofmann M, Spankuch I, et al
    Diagnostic accuracy of dermatofluoroscopy in cutaneous melanoma detection: Results of a prospective multicentre clinical study in 476 pigmented lesions.
    Br J Dermatol. 2018 Mar 22. doi: 10.1111/bjd.16565.
    PubMed     Text format     Abstract available


  36. MARCHAND A, Tallet A, Collin C, Cormier B, et al
    A rare BRAF T599dup mutation conferring sensitivity to BRAF inhibitor in a patient with metastatic melanoma.
    Br J Dermatol. 2018 Mar 1. doi: 10.1111/bjd.16499.
    PubMed     Text format     Abstract available


  37. BARRAGAN-ESTUDILLO ZF, Jesus-Silva MA, Chavez-Bourgeois MM, Brito J, et al
    Image Gallery: Transition pattern in acral melanoma.
    Br J Dermatol. 2018;178:e225.
    PubMed     Text format    


    February 2018
  38. LONGO C, Lallas A, Kyrgidis A, Bassoli S, et al
    Wide skin markings pattern - melanoma descriptor or patient-related factor?: reply from authors.
    Br J Dermatol. 2018 Feb 7. doi: 10.1111/bjd.16430.
    PubMed     Text format     Abstract available


  39. RISHPON A, Marchetti M, Marghoob A
    Wide skin markings pattern - melanoma descriptor or patient-related factor?
    Br J Dermatol. 2018 Feb 6. doi: 10.1111/bjd.16420.
    PubMed     Text format     Abstract available


  40. FUJISAWA Y, Yoshino K, Otsuka A, Funakoshi T, et al
    Baseline neutrophil to lymphocyte ratio combined with serum LDH level associated with outcome of nivolumab immunotherapy in a Japanese advanced melanoma population.
    Br J Dermatol. 2018 Feb 6. doi: 10.1111/bjd.16427.
    PubMed     Text format     Abstract available


  41. DANDO EE, Lim GFS, Ho J, James A, et al
    Image Gallery: Pigmented mammary Paget disease: a rare clinicopathological variant mimicking melanoma.
    Br J Dermatol. 2018;178:e143.
    PubMed     Text format    


  42. CUST AE
    Prognostic features for acral lentiginous melanoma.
    Br J Dermatol. 2018;178:311-312.
    PubMed     Text format    


  43. BELL KJL, Cust AE
    Beyond country-specific incidence and mortality: the global burden of melanoma.
    Br J Dermatol. 2018;178:315-316.
    PubMed     Text format    


    January 2018
  44. BORSARI S, Pampena R, Benati E, Bombonato C, et al
    In vivo dermoscopic and confocal microscopy multi-step algorithm to detect in situ melanomas.
    Br J Dermatol. 2018 Jan 21. doi: 10.1111/bjd.16364.
    PubMed     Text format     Abstract available


  45. LAINO AM, Berry EG, Jagirdar K, Lee KJ, et al
    Iris pigmented lesions as a marker of cutaneous melanoma risk: an Australian case-control study.
    Br J Dermatol. 2018 Jan 8. doi: 10.1111/bjd.16323.
    PubMed     Text format     Abstract available


  46. VERYKIOU S, Edwards N, Hill D
    How breakthroughs in translational research have impacted treatment strategies for melanoma.
    Br J Dermatol. 2018;178:5-8.
    PubMed     Text format    


  47. MUTHIAH S, Tang D, Nasr B, Verykiou S, et al
    A new era in holistic care: bridging the gap between dermatologists and oncologists for the treatment of malignant melanoma.
    Br J Dermatol. 2018;178:1-4.
    PubMed     Text format    


  48. WIESNER T, Zbyszewski A
    Progress in the diagnosis and therapy of melanoma.
    Br J Dermatol. 2018;178:12-14.
    PubMed     Text format    


  49. WEHNER MR
    Sunscreen and melanoma prevention: evidence and expectations.
    Br J Dermatol. 2018;178:15-16.
    PubMed     Text format    


  50. HWANG SJE, Fernandez-Penas P
    Pigmentary evolution with pembrolizumab use.
    Br J Dermatol. 2018;178:32-33.
    PubMed     Text format    


    December 2017
  51. MCINERNEY-LEO AM, Wheeler L, Sturm RA, Tan JM, et al
    Point mutation in p14(ARF) -specific exon 1beta of CDKN2A causing familial melanoma and astrocytoma.
    Br J Dermatol. 2017 Dec 26. doi: 10.1111/bjd.16275.
    PubMed     Text format     Abstract available


  52. DE UNAMUNO BUSTOS B, Murria Estal R, Perez Simo G, Simarro Farinos J, et al
    Aberrant DNA methylation is associated with aggressive clinicopathological features and poor survival in cutaneous melanoma.
    Br J Dermatol. 2017 Dec 26. doi: 10.1111/bjd.16254.
    PubMed     Text format     Abstract available


  53. SALOMON G, Maza A, Boulinguez S, Paul C, et al
    Efficacy of anti-PD-1 on skin carcinomas and melanoma metastases in an Xeroderma Pigmentosum patient.
    Br J Dermatol. 2017 Dec 23. doi: 10.1111/bjd.16270.
    PubMed     Text format     Abstract available


  54. OLSEN CM, Wilson LF, Green AC, Biswas N, et al
    How many melanomas might be prevented if more people applied sunscreen regularly?
    Br J Dermatol. 2017 Dec 14. doi: 10.1111/bjd.16079.
    PubMed     Text format     Abstract available


    November 2017
  55. WINSLOW UC, Nordestgaard BG, Afzal S
    High plasma 25-hydroxyvitamin D and high risk of non-melanoma skin cancer: a Mendelian randomisation study of 97849 individuals.
    Br J Dermatol. 2017 Nov 16. doi: 10.1111/bjd.16127.
    PubMed     Text format     Abstract available


  56. DEL PUERTO C, Navarrete-Dechent C, Molgo M, Camargo CA Jr, et al
    Immunohistochemical expression of vitamin D receptor in melanocytic nevi and cutaneous melanoma. A case-control study.
    Br J Dermatol. 2017 Nov 6. doi: 10.1111/bjd.16103.
    PubMed     Text format     Abstract available


    October 2017
  57. TRAN AD, Fogarty G, Nowak AK, Espinoza D, et al
    A systematic review and meta-analysis of utility estimates in melanoma.
    Br J Dermatol. 2017 Oct 27. doi: 10.1111/bjd.16098.
    PubMed     Text format     Abstract available


  58. SEO JW, Ha SM, Song KH
    Insulin-Like Growth Factor-II mRNA-Binding Protein 3 as a Novel Prognostic Biomarker for Acral Lentiginous Melanoma.
    Br J Dermatol. 2017 Oct 19. doi: 10.1111/bjd.16077.
    PubMed     Text format     Abstract available


  59. BASSOLI S, Kyrgidis A, Ciardo S, Casari A, et al
    Uncovering the diagnostic dermoscopic features of flat melanomas located on the lower limbs.
    Br J Dermatol. 2017 Oct 7. doi: 10.1111/bjd.16030.
    PubMed     Text format     Abstract available


  60. SCHAIDER H, Sturm RA
    The evolving universe of BRAF mutations in melanoma.
    Br J Dermatol. 2017;177:893.
    PubMed     Text format    


  61. ROBINSON JK, Spring B
    Personalized melanoma genomic risk information:perception of shared risk initiates sharing with family.
    Br J Dermatol. 2017;177:890-891.
    PubMed     Text format    


    September 2017
  62. SATTLER EC, Ertl-Wagner B, Pellegrini C, Peris K, et al
    Cutaneous melanoma in Birt-Hogg-Dube syndrome - part of the clinical spectrum?
    Br J Dermatol. 2017 Sep 4. doi: 10.1111/bjd.15937.
    PubMed     Text format     Abstract available


  63. ZNAOR A
    Melanoma burden, healthcare utilization and the potential for overdiagnosis in the elderly U.S. population.
    Br J Dermatol. 2017;177:625.
    PubMed     Text format    


    August 2017
  64. YOULDEN DR, Baade PD, Aitken JF, Green AC, et al
    Prognostic importance of a second invasive primary melanoma according to tumor stage.
    Br J Dermatol. 2017 Aug 3. doi: 10.1111/bjd.15863.
    PubMed     Text format     Abstract available


  65. BERK-KRAUSS J, Stein JA
    The role of access to care in acral lentiginous melanoma survival.
    Br J Dermatol. 2017;177:341-342.
    PubMed     Text format    


  66. HILL D, Lovat P
    Cover Image: Invasion of a cutaneous melanoma tumour.
    Br J Dermatol. 2017;177:599.
    PubMed     Text format    


    July 2017
  67. ADLER NR, Kelly JW, Haydon A, McLean CA, et al
    Clinicopathological characteristics and prognosis of patients with multiple primary melanomas.
    Br J Dermatol. 2017 Jul 28. doi: 10.1111/bjd.15855.
    PubMed     Text format     Abstract available


  68. DIAS-SANTAGATA D, Selim MA, Su Y, Peng Y, et al
    KIT Mutations and CD117 Overexpression Are Markers of Better Progression-Free Survival in Vulvar Melanomas.
    Br J Dermatol. 2017 Jul 22. doi: 10.1111/bjd.15836.
    PubMed     Text format     Abstract available


  69. TERAMOTO Y, Keim U, Gesierich A, Schuler G, et al
    Acral lentiginous melanoma - a skin cancer with unfavourable prognostic features. A study of the German Central Malignant Melanoma Registry (CMMR) in 2050 patients.
    Br J Dermatol. 2017 Jul 14. doi: 10.1111/bjd.15803.
    PubMed     Text format     Abstract available


  70. GIBBS DC, Ward SV, Orlow I, Cadby G, et al
    Functional melanoma-risk variant IRF4 rs12203592 associated with Breslow thickness: a pooled international study of primary melanomas.
    Br J Dermatol. 2017 Jul 1. doi: 10.1111/bjd.15784.
    PubMed     Text format     Abstract available


  71. MAHER NG, Guitera P
    Imiquimod treatment for lentigo maligna: LIMIT-1 trial.
    Br J Dermatol. 2017;177:324-325.
    PubMed     Text format    


    June 2017
  72. SMIT AK, Keogh LA, Newson AJ, Butow PN, et al
    Does personalised melanoma genomic risk information trigger conversations about skin cancer prevention and skin examination with family, friends and health professionals?
    Br J Dermatol. 2017 Jun 19. doi: 10.1111/bjd.15744.
    PubMed     Text format     Abstract available


  73. KIM SK, Barker CA
    Outcomes of radiation therapy for advanced T3/T4 non-melanoma cutaneous squamous cell and basal cell carcinoma.
    Br J Dermatol. 2017 Jun 15. doi: 10.1111/bjd.15728.
    PubMed     Text format     Abstract available


  74. CERIO R, Moir G
    Palliative electrochemotherapy treatment of metastatic malignant melanoma.
    Br J Dermatol. 2017;176:1427.
    PubMed     Text format    


  75. JONES G
    Methotrexate increases the risk of melanoma: or does it?
    Br J Dermatol. 2017;176:1429-1430.
    PubMed     Text format    


    May 2017
  76. RIBERO S, Carrera C, Tell-Marti G, Pastorino C, et al
    Amelanotic melanoma in oculocutaneous albinism: a genetic, dermoscopic and reflectance confocal microscopy study.
    Br J Dermatol. 2017 May 27. doi: 10.1111/bjd.15687.
    PubMed     Text format     Abstract available


  77. SWETTER SM
    Challenges of treating melanoma in situ, lentigo maligna type: is pathological clearance the gold standard?
    Br J Dermatol. 2017;176:1115-1116.
    PubMed     Text format    


  78. ELLIS RA
    T-type calcium channels as potential biomarkers in melanoma.
    Br J Dermatol. 2017;176:1122.
    PubMed     Text format    


  79. KRENGEL S, Reyes-Mugica M
    Melanoma risk in congenital melanocytic naevi.
    Br J Dermatol. 2017;176:1114.
    PubMed     Text format    


    April 2017
  80. DIXON A, Steinman H, Anderson S, Nirenberg A, et al
    Routine usage of sentinel node biopsy in melanoma management must cease: reply from authors.
    Br J Dermatol. 2017 Apr 29. doi: 10.1111/bjd.15626.
    PubMed     Text format     Abstract available


  81. SALEH DB
    RE: Routine usage of sentinel node biopsy in melanoma management must cease.
    Br J Dermatol. 2017 Apr 29. doi: 10.1111/bjd.15619.
    PubMed     Text format     Abstract available


  82. ASGARI MM, Shen L, Sokil MM, Yeh I, et al
    Prognostics factors and survival in acral lentiginous melanoma.
    Br J Dermatol. 2017 Apr 22. doi: 10.1111/bjd.15600.
    PubMed     Text format     Abstract available


  83. ROCHA L, Menzies SW, Lo S, Avramidis M, et al
    Analysis of an electrical impedance spectroscopy system in short-term digital dermoscopy imaging of melanocytic lesions.
    Br J Dermatol. 2017 Apr 19. doi: 10.1111/bjd.15595.
    PubMed     Text format     Abstract available


  84. GUALANO MR, Osella-Abate S, Scaioli G, Marra E, et al
    Prognostic role of Histologic regression in primary cutaneous melanoma: A Systematic Review and Meta-analysis.
    Br J Dermatol. 2017 Apr 7. doi: 10.1111/bjd.15552.
    PubMed     Text format     Abstract available


  85. NIJSTEN T, Wakkee M
    The four Ws of skin cancer surveillance in patients with melanoma: Why? Who? When? Where?
    Br J Dermatol. 2017;176:839-841.
    PubMed     Text format    


  86. MONTAUDIE H, Pradelli J, Passeron T, Lacour JP, et al
    Pulmonary sarcoid-like granulomatosis induced by nivolumab.
    Br J Dermatol. 2017;176:1060-1063.
    PubMed     Text format     Abstract available


    March 2017
  87. LOTT JP, Wang Q, Titus LJ, Onega T, et al
    Temporal Trends in Healthcare Utilization following Primary Melanoma Diagnosis among Medicare Beneficiaries.
    Br J Dermatol. 2017 Mar 30. doi: 10.1111/bjd.15530.
    PubMed     Text format     Abstract available


  88. KARIMKHANI C, Green AC, Nijsten T, Weinstock MA, et al
    The Global Burden of Melanoma: Results from Global Burden of Disease Study 2015.
    Br J Dermatol. 2017 Mar 30. doi: 10.1111/bjd.15510.
    PubMed     Text format     Abstract available


  89. KOGUCHI-YOSHIOKA H, Okiyama N, Iwamoto K, Matsumura Y, et al
    Intravenous immunoglobulin contributes to control anti-melanoma differentiation-associated protein 5 (MDA5) antibody-associated dermatomyositis with palmar violaceous macules/papules.
    Br J Dermatol. 2017 Mar 27. doi: 10.1111/bjd.15499.
    PubMed     Text format     Abstract available


  90. LICCIARDELLO M, T Giura M, Rozzo G, Marra E, et al
    Arrhythmias in metastatic melanoma patient treated with targeted therapy and ICD implant.
    Br J Dermatol. 2017 Mar 10. doi: 10.1111/bjd.15447.
    PubMed     Text format     Abstract available


  91. RICHTIG G, Hoeller C, Kashofer K, Aigelsreiter A, et al
    Beyond the BRAFV600E hotspot - Biology and clinical implications of rare BRAF gene mutations in melanoma patients.
    Br J Dermatol. 2017 Mar 9. doi: 10.1111/bjd.15436.
    PubMed     Text format     Abstract available


    February 2017
  92. CORR M, Roulston G, King N, Dornan T, et al
    Living with 'melanoma'...for a day: a phenomenological analysis of medical students' simulated experiences.
    Br J Dermatol. 2017 Feb 23. doi: 10.1111/bjd.15402.
    PubMed     Text format     Abstract available


  93. TSAI S, Scott JF, Keller JJ, Gerstenblith MR, et al
    Cutaneous malignancies identified on an inpatient Dermatology consult service.
    Br J Dermatol. 2017 Feb 23. doi: 10.1111/bjd.15401.
    PubMed     Text format     Abstract available


  94. JORDAN M, Ghoreschi K
    Anti-melanoma differentiation-associated protein 5 autoantibodies as a marker for dermatomyositis-associated interstitial lung disease.
    Br J Dermatol. 2017;176:294-295.
    PubMed     Text format    


    January 2017
  95. WOLNER ZJ, Marghoob AA, Pulitzer MP, Postow MA, et al
    A case report of disappearing pigmented skin lesions associated with pembrolizumab treatment for metastatic melanoma.
    Br J Dermatol. 2017 Jan 28. doi: 10.1111/bjd.15354.
    PubMed     Text format     Abstract available


  96. VANHAECKE C, Deilhes F, Chanal J, Regnier-Rosencher E, et al
    BRAFV600 inhibitor discontinuation after complete response in advanced melanoma. A retrospective analysis of 16 patients.
    Br J Dermatol. 2017 Jan 27. doi: 10.1111/bjd.15345.
    PubMed     Text format     Abstract available


  97. KUNTE C, Letule V, Gehl J, Dahlstroem K, et al
    Electrochemotherapy in the treatment of metastatic malignant melanoma: A prospective cohort study by InspECT.
    Br J Dermatol. 2017 Jan 24. doi: 10.1111/bjd.15340.
    PubMed     Text format     Abstract available


  98. MINAGAWA A, Omodaka T, Koga H, Yokokawa Y, et al
    Nail apparatus melanoma thickness is associated with side and age.
    Br J Dermatol. 2017 Jan 24. doi: 10.1111/bjd.15318.
    PubMed     Text format     Abstract available


  99. KINSLER VA, O'Hare P, Bulstrode N, Calonje JE, et al
    Melanoma in congenital melanocytic naevi.
    Br J Dermatol. 2017 Jan 12. doi: 10.1111/bjd.15301.
    PubMed     Text format     Abstract available


    December 2016
  100. NEITTAANMAKI N, Salmivuori M, Polonen I, Jeskanen L, et al
    Hyperspectral imaging in detecting dermal invasion in lentigo maligna melanoma.
    Br J Dermatol. 2016 Dec 23. doi: 10.1111/bjd.15267.
    PubMed     Text format     Abstract available


  101. USHER-SMITH JA, Kassianos AP, Emery JD, Abel GA, et al
    Identifying people at higher risk of melanoma across the U.K.: a primary-care-based electronic survey.
    Br J Dermatol. 2016 Dec 23. doi: 10.1111/bjd.15181.
    PubMed     Text format     Abstract available


  102. HERMS F, Franck N, Kramkimel N, Fichel F, et al
    Neutrophilic eccrine hidradenitis in 2 patients treated with BRAF inhibitors: a new cutaneous adverse event.
    Br J Dermatol. 2016 Dec 22. doi: 10.1111/bjd.15259.
    PubMed     Text format     Abstract available


  103. RICHTIG G, Richtig E, Kashofer K, Koch L, et al
    Testing and clinical implications for non-V600 BRAF mutations in metastatic NRASmt melanoma.
    Br J Dermatol. 2016 Dec 7. doi: 10.1111/bjd.15222.
    PubMed     Text format     Abstract available


  104. LINOS E, Li WQ, Han J, Li T, et al
    Lifetime UV exposure and Lentigo Maligna Melanoma.
    Br J Dermatol. 2016 Dec 7. doi: 10.1111/bjd.15218.
    PubMed     Text format     Abstract available


  105. SPENDER LC, Inman GJ
    Fatal attractions? Correlations of CXCL12-CXCR4-CXCR7 expression with disease progression in melanoma and Kaposi sarcoma.
    Br J Dermatol. 2016;175:1140-1141.
    PubMed     Text format    


  106. YELAMOS O, Nehal KS
    Integrating clinical information, dermoscopy and reflectance confocal microscopy to improve the diagnostic accuracy and confidence of amelanotic and lightly pigmented melanomas.
    Br J Dermatol. 2016;175:1147-1148.
    PubMed     Text format    


  107. HAASS NK
    JNK-ERK signalling in melanoma: rewired or entangled?
    Br J Dermatol. 2016;175:1139-1140.
    PubMed     Text format    


  108. DIXON A, Steinman H, Anderson S, Nirenberg A, et al
    Routine usage of sentinel node biopsy in melanoma management must cease.
    Br J Dermatol. 2016;175:1340-1341.
    PubMed     Text format    


    November 2016
  109. SPEIGL L, Janssen N, Weide B, Pawelec G, et al
    Prognostic impact of the putative cancer stem cell markers ABCG2, CD133, ALDH1A1 and CD44V7/8 in metastatic melanoma.
    Br J Dermatol. 2016 Nov 21. doi: 10.1111/bjd.15194.
    PubMed     Text format     Abstract available


  110. MAHER NG, Blumetti TP, Gomes EE, Cheng HM, et al
    Melanoma diagnosis may be a pitfall for optical coherence tomography assessment of equivocal amelanotic or hypomelanotic skin lesions.
    Br J Dermatol. 2016 Nov 18. doi: 10.1111/bjd.15187.
    PubMed     Text format     Abstract available


  111. POLESIE S, Gillstedt M, Sonnergren HH, Osmancevic A, et al
    Methotrexate Treatment and Risk for Cutaneous Malignant Melanoma - a Retrospective Comparative Registry-based Cohort Study.
    Br J Dermatol. 2016 Nov 10. doi: 10.1111/bjd.15170.
    PubMed     Text format     Abstract available


  112. BARRETT JH
    Telomere length and melanoma - is there a straightforward relationship?
    Br J Dermatol. 2016;175:865-866.
    PubMed     Text format    


  113. ELLIKER KR, Williams HC
    Detection of skin cancer odours using dogs: a step forward in melanoma detection training and research methodologies.
    Br J Dermatol. 2016;175:851-852.
    PubMed     Text format    


  114. EISEMANN N
    Routine health data in skin cancer screening evaluation.
    Br J Dermatol. 2016;175:862.
    PubMed     Text format    


    October 2016
  115. RICHTIG G, Byrom L, Kupsa R, Schaider H, et al
    Pregnancy as driver for melanoma.
    Br J Dermatol. 2016 Oct 8. doi: 10.1111/bjd.15124.
    PubMed     Text format     Abstract available


  116. MAIQUES O, Macia A, Moreno S, Barcelo C, et al
    Immunohistochemical analysis of T-type calcium channels in acquired melanocytic nevi and melanoma.
    Br J Dermatol. 2016 Oct 8. doi: 10.1111/bjd.15121.
    PubMed     Text format     Abstract available


  117. O'SHEA SJ, Davies JR, Newton-Bishop JA
    Vitamin D, vitamin A, the primary melanoma transcriptome and survival.
    Br J Dermatol. 2016;175 Suppl 2:30-34.
    PubMed     Text format     Abstract available


    September 2016
  118. PIZZICHETTA MA, Kittler H, Stanganelli I, Ghigliotti G, et al
    Dermoscopic diagnosis of amelanotic/hypomelanotic melanoma.
    Br J Dermatol. 2016 Sep 28. doi: 10.1111/bjd.15093.
    PubMed     Text format     Abstract available


  119. WEINSTOCK MA, Lott JP, Wang Q, Titus LJ, et al
    Skin Biopsy Utilization and Melanoma Incidence among Medicare Beneficiaries.
    Br J Dermatol. 2016 Sep 17. doi: 10.1111/bjd.15077.
    PubMed     Text format     Abstract available


  120. LO MC, Maraka J, Garioch J, John WG, et al
    Monitoring vitamin D in the melanoma patient - impact of sun avoidance on vitamin D levels of melanoma patients at a tertiary UK referral melanoma service.
    Br J Dermatol. 2016 Sep 17. doi: 10.1111/bjd.15062.
    PubMed     Text format     Abstract available


  121. FOX J
    A changing treatment paradigm: the role of palliative care in metastatic melanoma.
    Br J Dermatol. 2016;175:462-3.
    PubMed     Text format    


    June 2016
  122. WANG CC, Tang CH, Wang CY, Huang SY, et al
    Risk of skin cancer in chronic haemodialysis patients: a nationwide, population-based study in Taiwan.
    Br J Dermatol. 2016 Jun 7. doi: 10.1111/bjd.14789.
    PubMed     Text format     Abstract available


    May 2016
  123. GUITERA P, Menzies SW, Argenziano G, Longo C, et al
    Dermoscopy and in vivo confocal microscopy are complimentary techniques for the diagnosis of difficult amelanotic and light colored skin lesions.
    Br J Dermatol. 2016 May 13. doi: 10.1111/bjd.14749.
    PubMed     Text format     Abstract available


  124. LLOYD-LAVERY A, Hodgson T, Coupe N, Bond S, et al
    Delayed oral toxicity from long-term vemurafenib therapy.
    Br J Dermatol. 2016;174:1159-60.
    PubMed     Text format    


  125. LALLAS A, Tschandl P, Kyrgidis A, Stolz W, et al
    Dermoscopic clues to differentiate facial lentigo maligna from pigmented actinic keratosis.
    Br J Dermatol. 2016;174:1079-85.
    PubMed     Text format     Abstract available


  126. GREVELING K, de Vries K, van Doorn MB, Prens EP, et al
    A two-stage treatment of lentigo maligna using ablative laser therapy followed by imiquimod: excellent cosmesis, but frequent recurrences on the nose.
    Br J Dermatol. 2016;174:1134-6.
    PubMed     Text format    


    April 2016
  127. NILSEN LT, Hannevik M, Veierod MB
    Ultraviolet exposure from indoor tanning devices: a systematic review.
    Br J Dermatol. 2016;174:730-40.
    PubMed     Text format     Abstract available


    March 2016
  128. PARTARRIEU-MEJIAS F, Perez-Velasquez F
    Image Gallery: Xeroderma pigmentosum.
    Br J Dermatol. 2016;174:e12.
    PubMed     Text format    


  129. DE VRIES K, Greveling K, Prens LM, Munte K, et al
    Recurrence rate of lentigo maligna after micrographically controlled staged surgical excision.
    Br J Dermatol. 2016;174:588-93.
    PubMed     Text format     Abstract available


  130. BELLON T, Lerma V, Gonzalez-Valle O, Gonzalez Herrada C, et al
    Vemurafenib-induced toxic epidermal necrolysis: possible cross-reactivity with other sulfonamide compounds.
    Br J Dermatol. 2016;174:621-4.
    PubMed     Text format     Abstract available


    February 2016
  131. LEE S, Duffy DL, McClenahan P, Lee KJ, et al
    Heritability of naevus patterns in an adult twin cohort from the Brisbane Twin Registry: a cross-sectional study.
    Br J Dermatol. 2016;174:356-63.
    PubMed     Text format     Abstract available


    January 2016
  132. KAI AC, Richards T, Coleman A, Mallipeddi R, et al
    Five-year recurrence rate of lentigo maligna after treatment with imiquimod.
    Br J Dermatol. 2016;174:165-8.
    PubMed     Text format     Abstract available


    August 2015
  133. CHAVEZ-BOURGEOIS M, Iglesias P, Brito J, Malvehy J, et al
    Skin cancers detected as casual findings with Reflectance Confocal Microscopy (RCM) in the assessment of melasma treatment.
    Br J Dermatol. 2015 Aug 12. doi: 10.1111/bjd.14066.
    PubMed     Text format     Abstract available


    June 2015
  134. BENATI E, Zalaudek I, Piana S, Argenziano G, et al
    In vivo detection of peripheral clefting in melanocytic lesions.
    Br J Dermatol. 2015 Jun 23. doi: 10.1111/bjd.13959.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Malignant Melanoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: